

Dr. Wojciech Zareba from the University of Rochester refers to an ongoing NIH-sponsored trial of MTWA in MADIT-II patients.

"It is likely that SAECG and Microvolt T-Wave Alternans tests will emerge as routine for identifying low-risk and high-risk patients considered for ICD therapy." Results from this study are expected to be forthcoming in late 2011."

<http://money.cnn.com/news/newsfeeds/articles/marketwire/0585083.htm>

This study has been enrolling for quite some time and we were very encouraged to see Dr. Zareba's comments. Along with Dr. Arthur Moss, Dr. Zareba is part of a very well-respected team of researchers whose work has helped to establish many of the CRM guidelines in place today.